Trials / Suspended
SuspendedNCT00203593
Exercise and Prevention of Syncope: EXPOSE
EXercise for the Prevention of Syncope Evaluation
- Status
- Suspended
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- University of Calgary · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether eight weeks of exercise performed at an intensity of approximately 65% VO2max will improve symptoms associated with fainting (vasovagal syncope).
Detailed description
Background: Vasovagal syncope affects 20-30% of the population, and for those who faint recurrently it causes a significant reduction in the quality of life. Although significant progress has been made in the past 15 years in our understanding of its diagnosis and prognosis, our therapeutic attempts often end in failure. Many patients who have been diagnosed with vasovagal syncope have a reduced orthostatic tolerance. Improved orthostatic tolerance has been achieved through exercise in a number of studies on healthy individuals. However, its efficacy as a means of treatment for those with vasovagal syncope has not been thoroughly explored. Comparison: Subjects will be randomized to one of two groups: an exercise group or control. The exercise group will be asked to train at a target of approximately 65% of their maximum exercise capacity (VO2max) for 8 weeks/3 times per week. The control group will be asked to perform a series of neck rotation exercises. Orthostatic tolerance will be examined in both groups pre and post intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Exercise | |
| DEVICE | Blood volume | |
| PROCEDURE | VO2max test | |
| PROCEDURE | Lower body negative pressure | |
| BEHAVIORAL | Heart Rate | |
| PROCEDURE | Blood Pressure | |
| BEHAVIORAL | Total Peripheral Resistance |
Timeline
- Start date
- 2006-03-01
- Completion
- 2007-06-01
- First posted
- 2005-09-20
- Last updated
- 2007-03-14
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00203593. Inclusion in this directory is not an endorsement.